928788-22-1Relevant articles and documents
HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF
-
Paragraph 0241-0243, (2021/10/15)
The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein,wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.
SUBSTITUTED PYRIMIDODIAZEPINES
-
Page/Page column 7, (2008/12/08)
The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the t
5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
-
Page/Page column 40, (2010/11/26)
The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.
